Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer - Related Studies

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (Everest2)

This study is currently recruiting participants.

Verified February 2013 by Universitaire Ziekenhuizen Leuven

Study NCT01251536 Information provided by Universitaire Ziekenhuizen Leuven

First Received on December 1, 2010. Last Updated on February 25, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Colorectal Cancer

Additional conditions recognized in this trial

Colorectal Neoplasms

More general conditions related to this trial

Interventions listed in this trial

Additional drug interventions recognized in this trial

Cetuximab

More general drug interventions related to this trial

Sponsors listed in this trial